Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease
Briasoulis A, Inampudi C, Akintoye E, Alvarez P, Panaich S, Vaughan‐Sarrazin M. Safety and Efficacy of Novel Oral Anticoagulants Versus Warfarin in Medicare Beneficiaries With Atrial Fibrillation and Valvular Heart Disease. Journal Of The American Heart Association 2018, 7: e008773. PMID: 29622591, PMCID: PMC6015407, DOI: 10.1161/jaha.118.008773.Peer-Reviewed Original ResearchConceptsValvular heart diseaseAtrial fibrillationMedicare beneficiariesIschemic strokeHeart diseaseNew-onset atrial fibrillationNon-vitamin K anticoagulantsGastrointestinal bleeding ratesLarge community-based samplePropensity-matched sampleCommunity-based sampleMajor bleedingNongastrointestinal bleedingCause mortalitySystemic thromboembolismVersus WarfarinPrimary outcomePropensity matchingMyocardial infarctionBleeding rateLower riskPatientsRivaroxabanWarfarinDabigatran